Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
The chart shows the growth of an initial investment of $10,000 in Veracyte, Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Veracyte, Inc. (VCYT) has returned -23.47% so far this year and 18.22% over the past 12 months. Looking at the last ten years, VCYT has achieved an annualized return of 19.75%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Veracyte, Inc. (VCYT) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.63% | -3.99% | -9.36% | -0.17% | ||||||||
| 2025 | 13.47% | -20.73% | -14.63% | 2.80% | -13.15% | 1.73% | -12.28% | 30.49% | 13.71% | 5.22% | 31.61% | -9.79% |
| 2024 | -7.71% | -6.84% | -5.54% | -11.41% | 6.03% | 1.69% | 11.16% | 30.48% | 8.72% | -0.30% | 26.47% | -7.91% |
| 2023 | 3.46% | -2.69% | -9.13% | 2.35% | 14.46% | -1.13% | 8.11% | -3.15% | -16.55% | -6.96% | 23.67% | 8.01% |
| 2022 | -26.60% | -10.47% | -1.08% | -25.97% | -13.74% | 12.05% | 31.77% | -21.45% | -17.17% | 17.60% | 34.66% | -15.04% |
| 2021 | 16.14% | -0.51% | -9.71% | -9.41% | -22.21% | 2.07% | 10.38% | 7.75% | -4.35% | 3.86% | -13.35% | -2.62% |
| 2020 | -7.01% | -6.87% | -1.38% | 20.03% | -5.17% | 3.43% | 37.94% | -6.62% | -3.53% | 5.67% | 56.82% | -11.02% |
| 2019 | 48.98% | 11.04% | 23.25% | -10.21% | -7.05% | 25.76% | -3.70% | -6.19% | -8.22% | -4.54% | 23.85% | -2.89% |
| 2018 | -2.44% | -5.05% | -7.49% | 9.19% | 26.24% | 21.46% | 16.58% | 16.07% | -24.45% | 54.53% | -16.45% | 0.64% |
| 2017 | -4.77% | 4.31% | 16.79% | -7.73% | -4.91% | 1.09% | -4.19% | 1.11% | 6.95% | -3.17% | -20.89% | -3.97% |
| 2016 | 7.61% | -5.83% | -8.38% | -1.98% | 12.83% | 35.17% | -3.97% | 4.81% | 0.26% |
The charts below present risk-adjusted performance metrics for Veracyte, Inc. (VCYT) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of VCYT compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Veracyte, Inc. volatility is 3.26%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 1.41B | 1.11B | 1.16B | 1.19B | 457.16M | 275.21M | 120.64M | 78.67M | 101.03M | 75.29M | 64.84M | 79.63M |
| Equity Attributable To Parent (USD) | 1.31B | 1.04B | 1.08B | 1.10B | 421.23M | 239.46M | 79.76M | 37.23M | 59.58M | 51.25M | 41.37M | 56.44M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 1.31B | 1.04B | 1.08B | 1.10B | 421.23M | 239.46M | 79.76M | 37.23M | 59.58M | 51.25M | 41.37M | 56.44M |
| Noncurrent Liabilities (USD) | 36.51M | 9.56M | 18.61M | 27.16M | 19.15M | 18.29M | 27.82M | 29.42M | 29.92M | 9.31M | 6.32M | 7.80M |
| Other Current Liabilities (USD) | 27.89M | 21.87M | 20.07M | 21.00M | 4.46M | 5.04M | 4.13M | 2.88M | 2.99M | 5.43M | 7.08M | 8.13M |
| Wages (USD) | 27.46M | 26.43M | 30.64M | 30.79M | 9.20M | 10.10M | 6.41M | 5.29M | 6.12M | 4.21M | 2.67M | 1.96M |
| Accounts Payable (USD) | 4.59M | 12.94M | 11.91M | 12.36M | 3.12M | 2.33M | 2.52M | 3.85M | 2.42M | 5.09M | 7.40M | 5.29M |
| Current Liabilities (USD) | 59.94M | 61.24M | 62.61M | 64.15M | 16.78M | 17.47M | 13.06M | 12.03M | 11.53M | 14.72M | 17.15M | 15.39M |
| Liabilities (USD) | 96.44M | 70.80M | 81.22M | 91.31M | 35.93M | 35.76M | 40.88M | 41.44M | 41.45M | 24.03M | 23.47M | 23.19M |
| Other Non-current Assets (USD) | 828.50M | 740.69M | 715.22M | 726.89M | 72.49M | 78.59M | 14.75M | 15.05M | 15.93M | 17.04M | 17.33M | 271.00K |
| Intangible Assets (USD) | 89.15M | 88.59M | 174.87M | 202.73M | - | - | - | - | - | - | - | - |
| Fixed Assets (USD) | - | - | 17.70M | 15.10M | 8.99M | 8.93M | 8.94M | 9.69M | 11.48M | 10.31M | 4.16M | 2.95M |
| Noncurrent Assets (USD) | 917.64M | 829.29M | 907.79M | 944.72M | 81.48M | 87.53M | 23.69M | 24.74M | 27.41M | 27.35M | 21.49M | 3.22M |
| Other Current Assets (USD) | 467.83M | 52.99M | 55.44M | 231.88M | 371.02M | 180.88M | 93.55M | 48.60M | 70.15M | 44.17M | 39.65M | 73.84M |
| Inventory (USD) | 20.55M | 16.13M | 14.29M | 11.23M | 4.66M | 6.81M | 3.40M | 5.32M | 3.48M | 3.77M | 3.70M | 2.57M |
| Cash (USD) | - | 216.50M | 178.90M | - | - | - | - | - | - | - | - | - |
| Current Assets (USD) | 488.38M | 285.62M | 248.64M | 243.10M | 375.68M | 187.69M | 96.95M | 53.93M | 73.63M | 47.93M | 43.35M | 76.41M |
| Assets (USD) | 1.41B | 1.11B | 1.16B | 1.19B | 457.16M | 275.21M | 120.64M | 78.67M | 101.03M | 75.29M | 64.84M | 79.63M |
Healthcare companies are advancing precision medicine through gene therapy, AI diagnostics, and innovative treatments targeting age-related conditions, with several firms making significant breakthroughs in areas like longevity biotechnology and personalized care.
The Minimal Residual Disease (MRD) Testing Market is expected to grow at a CAGR of 11.18% from 2025 to 2030, driven by advancements in diagnostic technologies and the increasing focus on precision medicine and early relapse detection.
Veracyte is considering selling or shutting down its French subsidiary, which generates $4 million in revenue but incurs $7 million in fixed costs, leading to a $5 million loss. An analyst believes this could be a long-term positive for the company.
Insulet's Omnipod 5 has received FDA approval for type 2 diabetes patients, expanding its market potential. However, economic uncertainty and competitive pressures remain concerns for the company.
Globus Medical is gaining market share in the musculoskeletal solutions space, driven by strong performance of its products. However, the company is facing challenges from global economic factors, including rising costs and inflation.
Jens Holstein, a director at Veracyte Inc, sold 5,000 shares of the company's stock. The transaction suggests a neutral sentiment, as insider sales can be driven by various factors, including personal financial needs, rather than a negative outlook on the company's prospects.
Deteriorating geopolitical situation and supply bottlenecks mar the prospects of the Zacks Medical Instruments industry. Yet, HOLX, MASI and VCYT are worth buying based on strategic developments and fundamentals.
Veracyte, Steelcase and Applied Industrial have been highlighted in this Screen of The Week article.
Invest in companies like Veracyte (VCYT), Steelcase (SCS) and Applied Industrial Technologies (AIT), as they boast higher efficiency levels.
The mean of analysts' price targets for Veracyte (VCYT) points to a 37.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
